This is a preview of subscription content, log in via an institution to check access.
References
Palleroni AV, Aglione A, Dvorozniak MT, et al. The in vivo fate of PEG-interferon alpha-2a (Ro 25-3036) in tumor bearing mice [abstract no. 35]. 85th Annual Meeting of the American Association for Cancer Research; 1994 Apr 10–13; San Francisco, 310
Xu Z-X, Rakhit A, Patel IH, et al. PK/PD modeling approach to support clinical development of a long-acting interferon (RO 25-3036) for the treatment of chronic hepatitis C. Clin Pharmacol Ther 1998 Feb; 63: 162
Heathcote EJ, Pockros PJ, Fried MW, PEG-IFN alfa-2a Clinical Study Group, et al. The pharmacokinetics of pegylated-40K interferon alfa-2A in chronic hepatitis C patients with cirrhosis. Gastroenterology 1999 Apr; 116 (Pt 2): 735
Xu Z-X, Hoffman J, Patel I, et al. Single-dose safety/tolerability and pharmacokinetic/ pharmacodynamics following administration of ascending subcutaneous doses of pegylated-interferon and interferon alpha-2a to healthy subjects. Hepatology 1998 Oct; 28 Suppl. (Pt 2): 702
Shiffman M, Pockros PJ, Reddy RK, PEG-IFN alfa-2a Clinical Study Group, et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2A vs standard interferon alfa-2A for treatment of chronic hepatitis C. Gastroenterology 1999 Apr; 116 (Pt 2): 1275
‘Pegasys’: flying in the face of hepatitis C. Inpharma 1999 May 29; 1189: 9
Rights and permissions
About this article
Cite this article
PEG interferon-α-2a. Drugs R&D 2, 278–280 (1999). https://doi.org/10.2165/00126839-199902040-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902040-00016